Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Kissei Urges Halt to New Tavneos Use after Fatal Liver Injury Reports
May 18, 2026
-
REGULATORY MHLW Official Says US MFN Policy Could Be Taken Up by Chuikyo
May 15, 2026
-
REGULATORY Japan to Launch CEA “Technical Discussions” under MHLW Research Group
May 14, 2026
-
REGULATORY Mounjaro Hit with 25% Price Cut under Japan’s “SPA-SSS” Re-Pricing
May 14, 2026
-
REGULATORY Japan OKs Listing of Ambelvist, Dojolvi, Sohonos, and Finally Inrebic
May 14, 2026
-
REGULATORY Chuikyo Clears NHI Listing for Amchepry, Akuugo, and Zolgensma Intrathecal
May 14, 2026
-
REGULATORY Japan to Finalize 1st ALS Trial Guidelines This Year to Spur Global Development
May 13, 2026
-
BUSINESS Daiichi Targets 3 Trillion Yen Sales by FY2030, Global Top-5 Oncology Spot
May 12, 2026
-
BUSINESS Lilly Japan Hits Record Sales as Mounjaro Tops 100 Billion Yen
May 12, 2026
-
ACADEMIA Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
-
BUSINESS Daiichi Sankyo Cuts FY2025 Profit Outlook on ADC Supply Plan Review
May 11, 2026
-
BUSINESS J&J's Drug-Device Combo Offers Weeks-Long Local Therapy for Bladder Cancer: Exec
May 8, 2026
-
REGULATORY Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
-
BUSINESS Gilead Files Bictegravir Plus Lenacapavir HIV Pill in Japan
April 30, 2026
-
REGULATORY MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
April 28, 2026
-
REGULATORY Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
April 28, 2026
-
BUSINESS Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
April 28, 2026
-
REGULATORY Zepbound in Line for OSA Approval after Key Panel Nod
April 27, 2026
-
BUSINESS Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
-
BUSINESS Genmab Targets 2027 US Debut for 2 Cancer Drugs, CEO Eyes Blockbuster Potential
April 23, 2026
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…